US EUA For Lilly’s Bamlanivimab Conditioned On Additional GMP Compliance Requirements
Letter of authorization for COVID-19 therapeutic made at troubled Lilly plant requires independent third-party oversight.
You may also be interested in...
Under pressure to authorize use of Lilly’s bamlanivimab, the FDA must first weigh efficacy signals and GMP plant remediation progress.
Alkermes CRL is just the latest fallout from black-hole process.
Prospective new participants in benchmarking study must share manufacturing plant data by 20 November to see how they measure on quality against industry peers.